ReviewBiologics : targets & therapy2014
Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis.
Review in Biologics : targets & therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 31 citations in OpenAlex.
- Real-World Treatment and Care Patterns in Patients With Rheumatoid Arthritis Initiating First-Line Tumor Necrosis Factor Inhibitor Therapy in the United States.ACR open rheumatology · 2024Article
- A green-lipped mussel prevents rheumatoid arthritis via regulation of inflammatory response and osteoclastogenesis.PloS one · 2023Article
- Imperatorin Inhibits Proliferation, Migration, and InflammationACS omega · 2022Article
- Peripheral soluble epoxide hydrolase inhibition reduces hypernociception and inflammation in albumin-induced arthritis in temporomandibular joint of rats.International immunopharmacology · 2020Article
- Targeting Extracellular Vesicles to the Arthritic Joint Using a Damaged Cartilage-Specific Antibody.Frontiers in immunology · 2020Article
- Nitroxidized-Albumin Advanced Glycation End Product and Rheumatoid Arthritis.Archives of rheumatology · 2019Review
- Metformin ameliorates experimental-obesity-associated autoimmune arthritis by inducing FGF21 expression and brown adipocyte differentiation.Experimental & molecular medicine · 2018Article
- Biosimilars Have Arrived: Rituximab.Arthritis · 2018Review
- The clinical utility of gene expression examination in rheumatology.Mediterranean journal of rheumatology · 2017Review
- Patients' conceptions of their own influence on good treatment response to biological therapy in chronic inflammatory arthritis.Patient preference and adherence · 2017Article
- HtrA2 suppresses autoimmune arthritis and regulates activation of STAT3.Scientific reports · 2016Article
- Selective Inhibition of Membrane Type 1 Matrix Metalloproteinase Abrogates Progression of Experimental Inflammatory Arthritis: Synergy With Tumor Necrosis Factor Blockade.Arthritis & rheumatology (Hoboken, N.J.) · 2016Article
- Simultaneous inhibition of JAK and SYK kinases ameliorates chronic and destructive arthritis in mice.Arthritis research & therapy · 2015Article
- Blood-based identification of non-responders to anti-TNF therapy in rheumatoid arthritis.BMC medical genomics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The way rheumatoid arthritis is treated has changed dramatically with the introduction of anti-tumor necrosis factor (anti-TNF) biologics. Nevertheless, many patients still have less than adequate control of their disease activity even with these therapeutic regimens, and current knowledge fails to explain all the data already gathered. There is now a wide range of drugs from different classes of biologic disease-modifying anti-rheumatic drugs available (and soon this number will increase significantly), that provides the opportunity to address each patient as a particular case and thereby optimize medical intervention. Currently available biologics for the treatment of rheumatoid arthritis apart from anti-TNF-based therapies are reviewed, along with an analysis of the new insights they provide into the pathogenesis of the disease and a discussion of future prospects in the area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.